A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer-Reference-Cited by-同舟云学术

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

Published:2021-02 Issue:2 Volume:160 Page:418-426
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Chelariu-Raicu Anca,Nick Alpa,Urban Renata,Gordinier Mary,Leuschner Carola,Bavisotto Linda,Molin Graziela Zibetti Dal,Whisnant John K.,Coleman Robert L.

Funder

University of Texas MD Anderson Cancer Center

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference26 articles.

1. Relapsed ovarian cancer: challenges and management strategies for a chronic disease;Armstrong;Oncologist.,2002

2. Paclitaxel and its evolving role in the management of ovarian cancer;Kampan;Biomed. Res. Int.,2015

3. Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: a randomized clinical trial;Falchook;JAMA Oncol.,2019

4. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor;Fost;Oncol. Rep.,2011

5. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists;Liu;Clin. Cancer Res.,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncolytic Peptide‐Nanoplatform Drives Oncoimmune Response and Reverses Adenosine‐Induced Immunosuppressive Tumor Microenvironment;Advanced Healthcare Materials;2024-07-09

2. Engineering peptide drug therapeutics through chemical conjugation and implication in clinics;Medicinal Research Reviews;2024-05-05

3. Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer;Small;2024-02-11

4. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic;ACS Pharmacology & Translational Science;2024-01-24

5. ‘Renovation of old drugs’ – can peptide drug conjugates lead the post-ADC era?;Australian Journal of Chemistry;2023-06-30